Goldman Sachs Lifts Price Target On CVS Caremark (CVS)

Goldman Sachs raised its price target on Buy-rated CVS Caremark (NYSE: CVS) from $40 to $43 and adjusted estiamtes. The firm continues to see CVS as the best positioned drugstore.

2011 EPS goes from $2.76 to $2.79, Q4 remains unchanged and 2012 goes down a penny to $3.25. 2013 goes from $3.47 to $3.50 on retail expenses and interest expense.

"After years of controversy surrounding its retail/PBM consolidation, and a period of inconsistent execution, the firm is hovering above the dispute between ESRX and WAG, and delivering on PBM forecasts," the analyst stated.

For an analyst ratings summary and ratings history on CVS Caremark click here. For more ratings news on CVS Caremark click here.

Shares of CVS Caremark closed at $39.24 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• CVS Health (CVS) PT Raised to $114 at Argus
• Beike (BEKE) PT Raised to $23 at Morgan Stanley
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand